Sfoglia per AUTORE
TIEGHI A
Collezione AO Cuneo

  

Items : 17

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. in Blood cancer journal / Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU San Luigi di Orbassano

Andriani A; De Stefano V; Cavo M; Vianelli N; Abruzzese E; Latagliata R; Semenzato GC; Cuneo A; Lemoli RM; Krampera M; Bartoletti D; Cattaneo D; Santoni E; Ceglie S; D'Addio A; Rindone G; Mazzoni C; Romagnoli AD; Crugnola M; Miglino M; Bocchia M; Mendicino F; Tatarelli C; Cilloni D; Cavazzini F; Beggiato E; Caocci G; Binotto G; Polverelli N; et alii...

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. in Cancer / Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18.

2023
AOU Città della Salute di Torino
AO Cuneo

Cattaneo D; Bonifacio M; Cavo M; Vianelli N; Paglia S; Krampera M; Beggiato E; Abruzzese E; Bartoletti D; Cuneo A; Lemoli RM; Cilloni D; Semenzato G; Pane F; Heidel FH; Mazzoni C; Auteri G; Elli EM; Palumbo GA; Biondo M; Venturi M; Scaffidi L; Pugliese N; Martino B; Bosi C; Crugnola M; Palandri F; Bocchia M; Isidori A; et alii...

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. in Cancers / Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706.

2023
AO Cuneo
AOU Città della Salute di Torino

Lemoli RM; Semenzato G; Krampera M; Cuneo A; Pane F; Garibaldi B; Ripamonti A; Mullai R; Mazzoni C; Ceglie S; Polverelli N; Tomassetti S; Martino B; D'Addio A; Mendicino F; Crugnola M; Caocci G; Pugliese N; Heidel FH; Bonifacio M; Tieghi A; Tiribelli M; Binotto G; Cavazzini F; Elli EM; Benevolo G; Paglia S; Breccia M; Auteri G; et alii...

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. in Cancer / Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano

Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Breccia M; Palumbo GA; Micucci G; Ottaviani E; Martino B; Crugnola M; Binotto G; Bosi C; Pugliese N; Beggiato E; Fava C; Cavazzini F; Tieghi A; Benevolo G; Miglino M; Heidel FH; Polverelli N; Tiribelli M; Auteri G; Caocci G; et alii...

Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. in BMJ supportive & palliative care / BMJ Support Palliat Care. 2021 May 3:bmjspcare-2020-002312. doi: 10.1136/bmjspcare-2020-002312.

2021
AO Cuneo

Oswald LB; Venditti A; Cella D; Cottone F; Candoni A; Melillo L; Cairoli R; Storti G; Salutari P; Luppi M; Albano F; Martelli MP; Cuneo A; Tafuri A; Trisolini SM; Tieghi A; Fazi P; Vignetti M; Efficace F;

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. in Blood cancer journal / Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.

2021
AO Cuneo
AOU Città della Salute di Torino

Breccia M; Bonifacio M; Vianelli N; Cavo M; Iurlo A; Krampera M; Lemoli RM; Semenzato G; Cuneo A; Pane F; Stella R; Ciantia F; Trawinska MM; Cattaneo D; Scaffidi L; Bartoletti D; Auteri G; Heidel F; Pugliese N; Bosi C; Caocci G; Isidori A; Crugnola M; Bergamaschi M; Binotto G; Cavazzini F; Latagliata R; Tiribelli M; Tieghi A; et alii...

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. in Cancer / Cancer. 2021 Aug 1;127(15):2657-2665. doi: 10.1002/cncr.33541. Epub 2021 Apr 1.

2021
AO Cuneo
AOU Città della Salute di Torino

Bonifacio M; Palumbo GA; Vianelli N; Cavo M; Lemoli RM; Cuneo A; Krampera M; Semenzato G; Pane F; Latagliata R; Heidel FH; Bosi C; Crugnola M; Micucci G; Masselli E; Polverelli N; Scaffidi L; Stella R; Trawinska MM; Cattaneo D; Auteri G; Caocci G; Pugliese N; Binotto G; Abruzzese E; Tieghi A; Iurlo A; Martino B; Cavazzini F; et alii...

Second primary malignancy in myelofibrosis patients treated with ruxolitinib. in British journal of haematology / Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.

2021
AO Cuneo
AOU Città della Salute di Torino

Iurlo A; Cavo M; Russo D; Breccia M; Vianelli N; Lemoli RM; Semenzato G; Krampera M; Cuneo A; Catani L; Pane F; Markovic U; Stella R; Trawinska MM; Cattaneo D; D'Amore F; Scaffidi L; Martino B; Latagliata R; Gandolfi L; Auteri G; Bartoletti D; Bosi C; Isidori A; Pugliese N; Crugnola M; Heidel FH; Cavazzini F; Binotto G; et alii...

Second cancers in MPN: Survival analysis from an international study. in American journal of hematology / Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. Epub 2019 Dec 22.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli

Barbui T; Rambaldi A; Alvarez-Larran A; Vannucchi AM; Griesshammer M; Pane F; De Stefano V; Tieghi A; Isfort S; Recasens V; McMullin MF; Cacciola R; Carli G; Benevolo G; Angona A; Fox ML; Beggiato E; Lunghi F; Wille K; Perez-Encinas M; Rapezzi D; Erez D; Gomez M; Palova M; Casetti IC; Stephenson C; Elli EM; Guglielmelli P; Rumi E; et alii...

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. in Blood / Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara

Di Veroli A; Vannucchi AM; Barbui T; Rambaldi A; Griesshammer M; Alvarez-Larran A; Isfort S; Marchetti M; McMullin MF; Tieghi A; Recasens V; Carli G; Cacciola R; Benevolo G; Fox ML; Beggiato E; Lunghi F; Angona A; Wille K; Perez-Encinas M; Erez D; Gomez M; Rapezzi D; Palova M; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; et alii...

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. in Blood / Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.

2019
AO Cuneo

Amadori S; Arcese W; Lo-Coco F; Voso MT; Lavorgna S; Ottone T; Irno-Consalvo M; Del Principe MI; Buccisano F; Vignetti M; Maurillo L; Fazi P; La Sala E; Alati C; Fracchiolla NS; Capelli D; Foà R; Tieghi A; Chierichini A; Fabbiano F; Tafuri A; Cuneo A; Albano F; Mazza P; Martelli MP; Luppi M; Martinelli G; Lanza F; Storti G; et alii...

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. in Leukemia / Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.

2019
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli

Vannucchi AM; Alvarez-Larran A; Griesshammer M; Recasens V; Marchetti M; Tieghi A; McMullin MF; Cacciola R; Carli G; Benevolo G; Fox ML; Beggiato E; Perez-Encinas M; Lunghi F; Angona A; Wille K; Gomez M; Bertolotti L; Erez D; Palova M; Elli EM; Guglielmelli P; Casetti IC; Stephenson C; Patriarca A; Rumi E; Scaffidi L; Bonifacio M; Delaini F; et alii...

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. in Blood cancer journal / Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

2018
AO Cuneo

Arellano-Rodrigo E; Bellini M; Cazzola M; Censori B; Finazzi G; Rossi E; Betti S; Cortelezzi A; Cattaneo D; Loscocco GG; Lunghi F; Rapezzi D; Tieghi A; Gaidano G; Musolino C; Ellis MH; Beggiato E; Miroslava P; Carli G; Cacciola R; Hernandez-Boluda JC; Bonifacio M; Palandri F; Griesshammer M; Randi ML; Elli EM; Cervantes F; Rumi E; Finazzi MC; et alii...

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. in Hematological oncology / Hematol Oncol. 2018 Feb;36(1):285-290. doi: 10.1002/hon.2429. Epub 2017 May 17.

2018
AOU Città della Salute di Torino
AO Cuneo

Bonifacio M; Vianelli N; Cavo M; Scaffidi L; Cuneo A; Abruzzese E; Palumbo GA; Kallenberg L; Spinsanti M; Latagliata R; Martino B; Buccisano F; Heidel FH; Binotto G; Isidori A; Crugnola M; Polverelli N; Sgherza N; Bergamaschi M; Breccia M; Cavazzini F; Tieghi A; Benevolo G; Tiribelli M; Palandri F;

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

2017
AOU Città della Salute di Torino
AO Cuneo

Cuneo A; Cavo M; Vianelli N; Breccia M; Bacchi Reggiani ML; Merli F; Fanin R; Lemoli RM; Vitolo U; Di Raimondo F; Aversa F; Catani L; Sabattini E; Spinsanti M; De Matteis G; Anaclerico B; Cerqui E; de Marchi F; Scaffidi L; Di Veroli A; Latagliata R; Bosi C; Crugnola M; Ibatici A; Cavazzini F; Tieghi A; Bergamaschi M; Polverelli N; D'Adda M; et alii...

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. in Leukemia / Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. Epub 2016 Apr 26.

2016
AO Cuneo
AOU Novara

Barbui T; Vannucchi AM; Sant'Antonio E; Griesshammer M; Carobbio A; Musolino C; Rapezzi D; Forcina A; Pungolino E; Specchia G; Hernandez-Boluda JC; Tieghi A; Ellis MH; Cacciola R; Palova M; Cattaneo D; Nichele I; Betti S; Rossi E; Gaidano G; Zetterberg E; Vianelli N; Finazzi G; Finazzi MC; Elli E; Randi ML; Alvarez-Larrán A; Iurlo A; Ruggeri M; et alii...

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. in Blood cancer journal / Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.

2016
AO Cuneo

Barbui T; Griesshammer M; Carobbio A; Musolino C; Forcina A; Rapezzi D; Specchia G; Pungolino E; Hernandez-Boluda JC; Tieghi A; Cacciola E; Ellis MH; Palova M; Cattaneo D; Nichele I; Gaidano G; Vianelli N; Zetterberg E; Finazzi G; Finazzi MC; Elli E; Betti S; Guglielmelli P; Rossi E; Pieri L; Randi ML; Iurlo A; Alvarez-Larrán A; Cervantes F; et alii...